C
Christian Rolfo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 372
Citations - 16600
Christian Rolfo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 42, co-authored 320 publications receiving 12573 citations. Previous affiliations of Christian Rolfo include Mount Sinai Hospital & University of Palermo.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo,Philip C. Mack,Giorgio V. Scagliotti,Paul Baas,Fabrice Barlesi,Trever G. Bivona,Roy S. Herbst,Tony Mok,Nir Peled,Robert Pirker,Luis E. Raez,Martin Reck,Jonathan W. Riess,Lecia V. Sequist,Frances A. Shepherd,Lynette M. Sholl,Daniel Shao-Weng Tan,Heather A. Wakelee,Ignacio I. Wistuba,Murry W. Wynes,David P. Carbone,Fred R. Hirsch,David R. Gandara +22 more
TL;DR: It is concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.
Journal ArticleDOI
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon,Alexander Drilon,Salvatore Siena,Rafal Dziadziuszko,Fabrice Barlesi,Matthew G Krebs,Alice T. Shaw,Filippo de Braud,Christian Rolfo,Myung-Ju Ahn,Jürgen Wolf,Takashi Seto,Byoung Chul Cho,Manish R. Patel,Chao Hua Chiu,Thomas John,Koichi Goto,Christos S. Karapetis,Hendrick Tobias Arkenau,Sang We Kim,Yuichiro Ohe,Yu Chung Li,Young Kwang Chae,Christine H. Chung,Gregory A. Otterson,Haruyasu Murakami,Chia-Chi Lin,Daniel Shao-Weng Tan,Hans Prenen,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann D. Johnson,Susan Eng,Timothy R. Wilson,Robert C. Doebele +36 more
TL;DR: Entrectinib is active with durable disease control in patients with ROS1 fusion-positive NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-term dosing in these patients.
Journal ArticleDOI
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Udai Banerji,Carla M.L. van Herpen,Cristina Saura,Fiona C Thistlethwaite,Simon Lord,Victor Moreno,Iain R. Macpherson,Valentina Boni,Christian Rolfo,Elisabeth G.E. de Vries,Sylvie Rottey,Jill J.J. Geenen,Ferry A.L.M. Eskens,Marta Gil-Martin,E.C. Mommers,Norbert P Koper,Philippe Aftimos +16 more
TL;DR: This first-in-human study assessed the safety and activity of trastuzumab duocarmazine in patients with advanced solid tumours and the proportion of patients achieving an objective response (complete response or partial response) according to RECIST version 1.1.